Bevacizumab promising in locally advanced cervical cancer
A phase 2 trial of bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer found that adding bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3-year overall survival rates were 89.8% and 80.2%, respectively.
“Cervical cancer is a huge problem worldwide, but isn't as big a problem in the United States. So, in many ways, it tends to become a somewhat overlooked and under-studied disease,” said lead author Tracey Schefter, MD, of the University of Colorado Cancer Center in Aurora. The study was published in the International Journal of Radiation Oncology, Biology and Physics (2014;88:101-105).
Risk factors for cervical cancer include infection with the human papillomavirus (HPV). Screening dramatically reduces both the likelihood of developing cervical cancer and the disease's mortality rate. Combined, these two factors mean that 80% of the world's approximately 473,000 yearly cases of cervical cancer occur in the developing world. In the United States, cervical cancer rates have dropped 74% over the previous 50 years, but it is still diagnosed in approximately 10,000 women per year, with 3,500 deaths due to the disease.
The current phase 2 clinical trial, conducted by the Radiation Therapy Oncology Group (RTOG), and known as RTOG 0417, enrolled 49 eligible patients from 28 institutions in the years between 2006 and 2009. The study previously reported that bevacizumab was safe and well-tolerated in combination with cisplatin and radiation therapy in this population. Now the group reports on the secondary efficacy end points at a median follow-up time of 3.8 years.
Specifically, the group evaluated the addition of 10 mg/kg bevacizumab every 2 weeks for three cycles during chemoradiation. The overall survival and locoregional control results were favorable in comparison with historical controls of chemoradiation without bevacizumab and warrant further study in a phase 3 trial.
“Parenthetically, when we were designing this trial, one thing we discussed at length was whether to include a maintenance phase of bevacizumab after chemoradiation. Because of perceived issues with patient compliance at the time, we decided not to add to the overall duration of treatment by adding maintenance bevacizumab. Based on the recent results of GOG 240, which showed an overall survival benefit when bevacizumab was added to first-line chemotherapy for patients with metastatic disease, a trial addressing the benefit of both concurrent and maintenance bevacizumab for locoregionally advanced cervical cancer will likely need to be done,” Schefter said.